Cardinal Health (NYSE:CAH) announced today that the FDA approved its Lymphoseek injection for pediatric use.
Dublin, Ohio-based Cardinal Health touts Lymphoseek, which it acquired from Navidea Biopharmaceuticals (NYSE:NAVB) in November 2016, as the first and only radiopharmaceutical agent specifically designed for targeted lymphatic mapping nad guiding sentinel lymph node biopsies (SLNB).
Get the full story at our sister site, Drug Delivery Business News.